DE60038737D1 - Modifiziertes cytokin für seine stabilizierung - Google Patents

Modifiziertes cytokin für seine stabilizierung

Info

Publication number
DE60038737D1
DE60038737D1 DE60038737T DE60038737T DE60038737D1 DE 60038737 D1 DE60038737 D1 DE 60038737D1 DE 60038737 T DE60038737 T DE 60038737T DE 60038737 T DE60038737 T DE 60038737T DE 60038737 D1 DE60038737 D1 DE 60038737D1
Authority
DE
Germany
Prior art keywords
cytokin
stabilization
modified
modified cytokin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60038737T
Other languages
English (en)
Other versions
DE60038737T2 (de
Inventor
Helena Domingues
Hartmut Oschkinat
Luis Serrano
Joerg Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Europaisches Laboratorium fuer Molekularbiologie EMBL
Bayer Pharma AG
Original Assignee
Europaisches Laboratorium fuer Molekularbiologie EMBL
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europaisches Laboratorium fuer Molekularbiologie EMBL, Bayer AG filed Critical Europaisches Laboratorium fuer Molekularbiologie EMBL
Application granted granted Critical
Publication of DE60038737D1 publication Critical patent/DE60038737D1/de
Publication of DE60038737T2 publication Critical patent/DE60038737T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60038737T 1999-05-26 2000-05-23 Modifiziertes cytokin für seine stabilizierung Expired - Lifetime DE60038737T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9912350 1999-05-26
GBGB9912350.7A GB9912350D0 (en) 1999-05-26 1999-05-26 Modified cytokine
PCT/IB2000/000769 WO2000073460A2 (en) 1999-05-26 2000-05-23 Modified cytokine for its stabilisation

Publications (2)

Publication Number Publication Date
DE60038737D1 true DE60038737D1 (de) 2008-06-12
DE60038737T2 DE60038737T2 (de) 2009-07-02

Family

ID=10854271

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60038737T Expired - Lifetime DE60038737T2 (de) 1999-05-26 2000-05-23 Modifiziertes cytokin für seine stabilizierung

Country Status (9)

Country Link
US (1) US7112660B1 (de)
EP (1) EP1183360B1 (de)
JP (1) JP2003501035A (de)
AU (1) AU4943200A (de)
CA (1) CA2372566A1 (de)
DE (1) DE60038737T2 (de)
ES (1) ES2304957T3 (de)
GB (1) GB9912350D0 (de)
WO (1) WO2000073460A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314739A1 (de) 2001-11-22 2003-05-28 Bayer Ag Verfahren zur Renaturierung rekombinanter, Disulfid-enthaltender Proteine bei hohen Proteinkonzentrationen in Gegenwart von Aminen
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
DK1572127T4 (da) 2002-02-14 2014-11-24 Univ Leland Stanford Junior Enzymbehandling af fødevarer til cøliaki
DK1563300T3 (da) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US10059756B2 (en) * 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
TW201940502A (zh) * 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2136833B1 (de) * 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Kombinationsenzymtherapie zum aufschluss von gluten in der nahrung
US8148105B2 (en) * 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
CN102216323B (zh) * 2008-11-17 2016-08-03 哥本哈根大学 用于调节慢性炎症反应和治疗自身免疫性疾病的源自il-4的肽
US9688735B2 (en) * 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
WO2013106485A2 (en) * 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
WO2014197535A1 (en) * 2013-06-04 2014-12-11 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
AU2014296107B2 (en) * 2013-07-31 2018-07-26 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
US11072647B2 (en) * 2013-12-19 2021-07-27 Onsejo Nacional DE Investigation Cientiticay Tecnica TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
EP3673915A1 (de) 2014-06-30 2020-07-01 Altor BioScience Corporation Il-15-basierte moleküle und verfahren zur verwendung davon
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
CR20170027A (es) * 2014-07-30 2017-05-09 Ngm Biopharmaceuticals Inc Composiciones y métodos de uso para tratar trastornos metabólicos
TWI703161B (zh) * 2014-10-31 2020-09-01 美商Ｎｇｍ生物製藥公司 用於治療代謝病症之組合物及方法
ITMI20150558A1 (it) * 2015-04-16 2016-10-16 Univ Politecnica Delle Marche Irisina per la cura e la prevenzione dell'osteoporosi
WO2016186071A1 (ja) * 2015-05-20 2016-11-24 国立大学法人大阪大学 炎症性サイトカイン分泌抑制活性を有するオリゴペプチド
WO2016196429A1 (en) * 2015-06-03 2016-12-08 The Medical College Of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
US11571462B2 (en) * 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
US10940200B2 (en) * 2015-09-28 2021-03-09 East Carolina University Aluminum based adjuvants for tolerogenic vaccination
AU2016361461B2 (en) * 2015-11-26 2020-10-22 Hudson Institute of Medical Research Inhibin analogs
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
WO2017176938A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
PT3496739T (pt) * 2016-07-15 2021-06-21 Acceleron Pharma Inc Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
WO2018018082A1 (en) * 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
AU2017302282A1 (en) * 2016-07-27 2019-02-07 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
EP3606562A4 (de) * 2017-04-03 2020-11-11 Acceleron Pharma Inc. Zusammensetzungen und verfahren zur behandlung von spinaler muskelatrophie
EP3512874A2 (de) * 2017-11-30 2019-07-24 Grifols Diagnostic Solutions Inc. Immunoassays und manipulierte proteine zur überwachung von antikörperbehandlungen gegen die immun-checkpoint-inhibitoren pd-1 und pd-l1
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
EP3553081A1 (de) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Natriuretische peptidgepfropfte antikörper im vorhof
CN112638406A (zh) * 2018-06-22 2021-04-09 科优基因公司 白介素-2变体及其使用方法
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
CN112638935A (zh) * 2019-01-27 2021-04-09 中国医药大学 一种类风湿性关节炎自体抗体结合的肽及其应用
CA3137512A1 (en) * 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
US11851490B2 (en) * 2019-08-15 2023-12-26 Northwestern University Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
JP2023548045A (ja) 2020-10-23 2023-11-15 アッシャー バイオセラピューティクス， インコーポレイテッド 免疫細胞機能をモジュレートするためのｃｄ８抗原結合分子を有する融合物
WO2022144836A1 (en) * 2020-12-31 2022-07-07 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
IL308609A (en) * 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13

Also Published As

Publication number Publication date
EP1183360B1 (de) 2008-04-30
GB9912350D0 (en) 1999-07-28
WO2000073460A3 (en) 2001-10-18
US7112660B1 (en) 2006-09-26
ES2304957T3 (es) 2008-11-01
DE60038737T2 (de) 2009-07-02
AU4943200A (en) 2000-12-18
CA2372566A1 (en) 2000-12-07
JP2003501035A (ja) 2003-01-14
WO2000073460A2 (en) 2000-12-07
EP1183360A2 (de) 2002-03-06

Similar Documents

Publication Publication Date Title
DE60038737D1 (de) Modifiziertes cytokin für seine stabilizierung
ID29550A (id) Quinolinakarboksamida sebagai agen-agen antivirus
PT1084114E (pt) Derivados isotiazole uteis como agentes anticancerigenos
DE50015294D1 (de) Mikrotom
NO20016115D0 (no) Substituerte heterocykelkondenserte gamma-karboliner
PT1224180E (pt) Azois substituidos
DE60030202D1 (de) Stabhalter
EE04027B1 (et) Puhverseadis
DK1307744T3 (da) Analyseapparat
DE69928765D1 (de) Inspektionssystem
ATE316978T1 (de) Ent-steroide als selektiv wirksame estrogene
DE50013404D1 (de) Substituierte 2-dialkylaminoalkylbiphenyl-derivate
FI981704A0 (fi) Sauva
DE50011908D1 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
NO20022564L (no) Nye androgener
DE69930941D1 (de) Pektinstoff als wachstumfaktor stabilizierungmittel
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
DE69900351T2 (de) Prüfkopfanordnung
NO20022927L (no) Substituerte pyrrazoler
DK1194426T3 (da) Benzofuranderivater
DE60030066D1 (de) Prüfgerät
PT1121349E (pt) Tiadiazolsulfonamidas substituidas como inibidores de interleucina-1-beta
DE60123315D1 (de) Analysegerät
DE50003921D1 (de) Substituierte phenyluracile
PT1380585E (pt) Pirazolopiridinona como intermediario

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE

Owner name: EUROPEAN MOLECULAR BIOLOGY LABORATORY, 69117 H, DE

R082 Change of representative

Ref document number: 1183360

Country of ref document: EP

Representative=s name: WITTE, WELLER & PARTNER, DE